American Journal of Clinical Oncology-Cancer Clinical Trials

Papers
(The H4-Index of American Journal of Clinical Oncology-Cancer Clinical Trials is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Efficacy and Safety of Pegylated Filgrastim as Primary Prophylaxis Following Pediatric Dose-intensive Chemotherapy64
Validation of Spanish-Language Surveys Utilized for the Navigator-Assisted Hypofractionation (NAVAH) Program to Aid Hispanic-American Breast Cancer Patients24
Nomogram Predicting Grade ≥2 Acute Radiation Enteritis in Patients With Cervical Cancer Receiving Concurrent Chemoradiotherapy24
Pharmacokinetics-Pharmacodynamics Modeling and Evaluation of Tumor Response to Bortezomib Proteasome Inhibitor in Waldenstrom Macroglobulinemia23
Endpoint Governance and Reporting Transparency in Biomarker-Guided Oncology Trials22
The Prognostic Significance of the Depth of Cervical Stromal Invasion in Women With FIGO Stage II Uterine Endometrioid Carcinoma18
Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors15
The Impact of Patient, Disease, and Social Determinants of Health on Receipt of Nonoperative Management for Patients With Rectal Adenocarcinoma15
Death From Infection Among Patients Living With Cancer14
The Landscape of Clinical Trials for Claudin18.2-Positive Gastric Cancer14
Does Examined Lymph Node Count Influence Survival in Surgically Resected Early‑stage Pulmonary Typical Carcinoid Tumors?14
Lack of Impact of Expansion Size From Gross Tumor Volume to Planning Target Volume on Control Rates and Patterns of Recurrence in Fractionated Radiotherapy for WHO Grade 1 Meningiomas13
Efficacy and Prognostic Factors of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer13
The Prognostic and Functional Impact of Sprouty 2 Expression in Non–small Cell Lung Cancer13
Heart Disease Mortality After Primary Cancer Surgery in the United States13
0.28866291046143